Skip to Content

News Release

BioScrip Announces Availability of ALS Home Infusion Therapy

October 5, 2017 at 8:00 AM EDT

DENVER, Oct. 05, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, is pleased to announce that it can now dispense and administer Radicava® (edaravone), the first treatment option for amyotrophic lateral sclerosis (ALS) approved by the U.S. Food and Drug Administration (FDA) in more than 20 years. Radicava is commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. (MTPA).

“Seeing the potential benefit to our patients, BioScrip registered in the MTPA National Directory as a provider for this important therapy as soon as it was approved,” said Robert Roose, Senior Vice President and Chief Procurement Officer at BioScrip. “Receiving the approval as a provider of choice to dispense and administer this limited distribution drug underscores the fact that BioScrip is a destination of choice for our manufacturers.”

BioScrip will provide Radicava in the patient’s home or in an infusion suite setting, depending on the patient’s care plan and condition. These capabilities include providing the first dose of Radicava where the patient’s care plan permits. BioScrip will assist caregivers and patients to be independent with Radicava therapy in the comfort of their own home, when approved by the prescriber. Prescribers may find a list of BioScrip’s infusion pharmacies and infusion suites by visiting the Company’s website at

Radicava is administered through intravenous infusion in 28-day cycles. Treatment usually starts with a patient receiving the therapy for 14 consecutive days, followed by a two-week therapy-free period. The next cycle begins with an infusion during 10 of the next 14 days, followed by another two-week treatment-free period. The infusion of each 60mg dose takes one hour.

About BioScrip

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Important Safety Information

Before you receive RADICAVA, tell your healthcare provider about all of your medical conditions, including if you:

  • have asthma.
  • are allergic to other medicines.
  • are pregnant or plan to become pregnant. It is not known if RADICAVA will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if RADICAVA passes into your breast milk. You and your healthcare provider should decide if you will receive RADICAVA or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of RADICAVA?

  • RADICAVA may cause serious side effects including hypersensitivity (allergic) reactions and sulfite allergic reactions. 
  • Hypersensitivity reactions have happened in people receiving RADICAVA and can happen after your infusion is finished.
  • RADICAVA contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe asthma episodes in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma.
  • Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: hives; swelling of the lips, tongue, or face; fainting; breathing problems; wheezing; trouble swallowing; dizziness; itching; or an asthma attack (in people with asthma).
  • Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects.

The most common side effects of RADICAVA include bruising (contusion), problems walking (gait disturbance), and headache.

These are not all the possible side effects of RADICAVA. Call your healthcare provider for medical advice about side effects. You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or

For more information, including full prescribing information and patient information, please visit

Robert Roose 

Primary Logo

Source: BioScrip, Inc.